TY - JOUR
T1 - Use of the experience sampling method in adolescents with Duchenne muscular dystrophy
T2 - a feasibility study
AU - Lionarons, Judith M.
AU - Delespaul, Philippe A.E.G.
AU - Hellebrekers, Danique M.J.
AU - Broen, Martinus P.G.
AU - Klinkenberg, Sylvia
AU - Faber, Catharina G.
AU - Hendriksen, Jos G.M.
AU - Vles, Johan S.H.
N1 - Funding Information:
The research was funded by Duchenne Parent Project NL, Spieren voor spieren NL (Grant No. SvS15-) and the School for Mental Health and Neuroscience of Maastricht University. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2023, The Author(s).
PY - 2024/7
Y1 - 2024/7
N2 - Experience sampling methods (ESM) using mobile health (mHealth) technology with a smartphone application are increasingly used in clinical practice and research. Still, recommendations are limited in young people, and adaptations may be necessary. Patients with Duchenne muscular dystrophy (DMD) are chronically treated with steroids from a young age. However, the impact of intermittent treatment schedules on fluctuations in somatic, cognitive and behavioural symptoms is poorly investigated. Existing studies are often cross-sectional and occur in controlled clinical settings, which do not provide sufficiently detailed insights into possible correlations. ESM might alleviate these problems. ESM innovates data collection with a smartphone application, which repeatedly assesses specific symptoms and contextual factors at random moments in daily life. We aimed to evaluate its feasibility in adolescents with DMD. In three (without/with/without steroids) 4-day periods of ESM, that were nested in 10/10 or 11/9 day on/off-medication periods, we evaluated its user-friendliness and compliance, and explored its ability to objectify fluctuations in somatic, cognitive and behavioural symptom severity and their relationship with contextual factors in seven DMD patients (age range 12–18 years) using intermittent corticosteroid treatment (dosage range 0.3–0.6 mg/kg/day). Patients reported that ESM was convenient and user-friendly. We were able to capture extensive intra-individual symptom fluctuations during intermittent corticosteroid treatment that were not revealed by routine clinical assessment. Implementing ESM to evaluate symptom fluctuation patterns in relation to treatment effects shows promise in adolescents with DMD. Optimization in further research is needed.
AB - Experience sampling methods (ESM) using mobile health (mHealth) technology with a smartphone application are increasingly used in clinical practice and research. Still, recommendations are limited in young people, and adaptations may be necessary. Patients with Duchenne muscular dystrophy (DMD) are chronically treated with steroids from a young age. However, the impact of intermittent treatment schedules on fluctuations in somatic, cognitive and behavioural symptoms is poorly investigated. Existing studies are often cross-sectional and occur in controlled clinical settings, which do not provide sufficiently detailed insights into possible correlations. ESM might alleviate these problems. ESM innovates data collection with a smartphone application, which repeatedly assesses specific symptoms and contextual factors at random moments in daily life. We aimed to evaluate its feasibility in adolescents with DMD. In three (without/with/without steroids) 4-day periods of ESM, that were nested in 10/10 or 11/9 day on/off-medication periods, we evaluated its user-friendliness and compliance, and explored its ability to objectify fluctuations in somatic, cognitive and behavioural symptom severity and their relationship with contextual factors in seven DMD patients (age range 12–18 years) using intermittent corticosteroid treatment (dosage range 0.3–0.6 mg/kg/day). Patients reported that ESM was convenient and user-friendly. We were able to capture extensive intra-individual symptom fluctuations during intermittent corticosteroid treatment that were not revealed by routine clinical assessment. Implementing ESM to evaluate symptom fluctuation patterns in relation to treatment effects shows promise in adolescents with DMD. Optimization in further research is needed.
KW - Behaviour
KW - Cognition
KW - Duchenne muscular dystrophy
KW - Experience sampling method
KW - mHealth
KW - Steroid treatment
U2 - 10.1007/s00787-023-02317-2
DO - 10.1007/s00787-023-02317-2
M3 - Article
SN - 1018-8827
VL - 33
SP - 2281
EP - 2290
JO - European Child & Adolescent Psychiatry
JF - European Child & Adolescent Psychiatry
IS - 7
ER -